Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04474210 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Renal Impairment on JNJ-56136379 in Adult Participants
A Phase 1 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT04474210: Clinical Trial Phase 1 study, sponsored by Janssen Research & Development.
NCT04474210 is a Phase 1 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04474210, a Phase 1 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) of a single oral dose of JNJ-56136379 in adult participants with renal impairment compared with healthy participants with normal renal function.
Primary Outcome
Cmax is defined as the maximum observed plasma analyte concentration.
Interventions
- DRUG JNJ-56136379
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-08-19 |
| Est. Completion | 2020-11-30 |
| Phase | Phase 1 |
Why NCT04474210 stopped before completion
NCT04474210 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which JNJ-56136379 is the first listed.
NCT04474210 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04474210 about?
NCT04474210 is a clinical study titled "A Study to Evaluate the Effect of Renal Impairment on JNJ-56136379 in Adult Participants". The purpose of this study is to evaluate the pharmacokinetics (PK) of a single oral dose of JNJ-56136379 in adult participants with renal impairment compared with healthy participants with normal renal function.
What is the current status of trial NCT04474210?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2020-08-19. Estimated completion is 2020-11-30.
What interventions are being tested in trial NCT04474210?
The interventions under investigation include: JNJ-56136379 (DRUG).
Who is sponsoring clinical trial NCT04474210?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04474210's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI